Advertisement
Singapore markets close in 3 hours 5 minutes
  • Straits Times Index

    3,172.91
    -14.75 (-0.46%)
     
  • Nikkei

    37,169.62
    -910.08 (-2.39%)
     
  • Hang Seng

    16,153.98
    -231.89 (-1.42%)
     
  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     
  • Bitcoin USD

    62,109.71
    +711.55 (+1.16%)
     
  • CMC Crypto 200

    1,278.85
    +393.31 (+42.84%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,396.10
    -1.90 (-0.08%)
     
  • Crude Oil

    84.33
    +1.60 (+1.93%)
     
  • 10-Yr Bond

    4.6470
    -4.5850 (-49.66%)
     
  • FTSE Bursa Malaysia

    1,551.42
    +6.66 (+0.43%)
     
  • Jakarta Composite Index

    7,063.10
    -103.72 (-1.45%)
     
  • PSE Index

    6,421.29
    -101.90 (-1.56%)
     

Three Healthcare Stocks Rallying Over 10% Today

Three Healthcare Stocks Rallying Over 10% Today

Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.